Holen Sie sich die Stockscreener-App
1.91
5.52%
0.10
Vorhandelsmarkt:
1.89
-0.02
-1.05%
Schlusskurs vom Vortag:
$1.81
Offen:
$1.84
24-Stunden-Volumen:
1.35M
Relative Volume:
1.66
Marktkapitalisierung:
$152.29M
Einnahmen:
$63.63M
Nettoeinkommen (Verlust:
$10.62M
KGV:
38.20
EPS:
0.05
Netto-Cashflow:
$-8.64M
1W Leistung:
+20.89%
1M Leistung:
+29.05%
6M Leistung:
-14.73%
1J Leistung:
+81.90%
1-Tages-Spanne:
$1.81
$1.94
1-Wochen-Bereich:
$1.59
$1.94
52-Wochen-Spanne:
$0.99
$3.10
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Firmenname
Protalix BioTherapeutics Inc.
Sektor
Branche
Telefon
972 4 988 9488
Adresse
2 Snunit Street, Science Park PO Box 455, Karmiel
Vergleichen Sie PLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
1.91 | 144.32M | 63.63M | 10.62M | -8.64M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.21 | 101.15B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.14 | 61.07B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.59 | 59.35B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.83 | 46.29B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.27 | 35.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-17 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-04-04 | Eingeleitet | Rodman & Renshaw | Buy |
| 2015-04-23 | Hochstufung | Jefferies | Hold → Buy |
| 2014-11-12 | Bestätigt | R. F. Lafferty | Buy |
| 2014-01-24 | Eingeleitet | R. F. Lafferty | Buy |
| 2012-05-02 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-04-30 | Herabstufung | Auriga | Buy → Hold |
| 2011-10-13 | Eingeleitet | Morgan Joseph | Hold |
| 2011-03-17 | Herabstufung | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | Bestätigt | Oppenheimer | Outperform |
| 2010-10-14 | Bestätigt | UBS | Buy |
| 2009-12-02 | Bestätigt | Hapoalim | Outperform |
| 2009-09-22 | Eingeleitet | Canaccord Adams | Buy |
| 2009-09-02 | Eingeleitet | Hapoalim | Outperform |
| 2008-12-01 | Bestätigt | Oppenheimer | Outperform |
| 2008-03-11 | Eingeleitet | UBS | Buy |
| 2007-11-20 | Eingeleitet | CIBC Wrld Mkts | Sector Outperform |
Alle ansehen
Protalix BioTherapeutics Inc. Aktie (PLX) Neueste Nachrichten
Multi factor analysis applied to Protalix BioTherapeutics Inc.2025 Support & Resistance & Weekly Momentum Picks - newser.com
Will Protalix BioTherapeutics Inc. see short term momentumJuly 2025 Action & Risk Controlled Stock Alerts - newser.com
Will a bounce in Protalix BioTherapeutics Inc. offer an exitShare Buyback & Verified Trade Idea Suggestions - newser.com
Visual trend scoring systems applied to Protalix BioTherapeutics Inc.IPO Watch & Community Driven Trade Alerts - newser.com
Fed Meeting: Is Protalix BioTherapeutics Inc a strong candidate for buy and hold2025 Earnings Impact & Real-Time Chart Pattern Alerts - خودرو بانک
Protalix BioTherapeutics Inc. stock prediction for this weekJuly 2025 Trends & Precise Trade Entry Recommendations - newser.com
Breakouts Watch: How correlated is The New York Times Company to the S&P500July 2025 Macro Moves & Free Fast Entry Momentum Trade Alerts - خودرو بانک
Does Protalix BioTherapeutics Inc have a competitive edge2025 Support & Resistance & Verified Short-Term Plans - خودرو بانک
Regression analysis insights on Protalix BioTherapeutics Inc. performanceJuly 2025 Fed Impact & Community Verified Trade Signals - newser.com
Technical analysis overview for Protalix BioTherapeutics Inc. stockTrade Performance Summary & Community Verified Watchlist Alerts - newser.com
What to expect from Protalix BioTherapeutics Inc. in the next 30 days2025 Price Action Summary & Free Real-Time Volume Trigger Notifications - newser.com
Statistical indicators supporting Protalix BioTherapeutics Inc.’s strength2025 Institutional Moves & Consistent Growth Stock Picks - newser.com
Protalix BioTherapeutics appoints Gilad Mamlok as CFO - MSN
Strategies to average down on Protalix BioTherapeutics Inc.Weekly Loss Report & Reliable Entry Point Alerts - Newser
What MACD and RSI say about Protalix BioTherapeutics Inc.Options Play & Precise Trade Entry Recommendations - Newser
Is Protalix BioTherapeutics Inc. stock bottoming outRate Cut & Real-Time Volume Trigger Notifications - Newser
What recovery options are there for Protalix BioTherapeutics Inc.Portfolio Return Summary & Fast Gaining Stock Strategy Reports - Newser
Sector ETF performance correlation with Protalix BioTherapeutics Inc.2025 Valuation Update & AI Powered Market Trend Analysis - Newser
Short interest data insights for Protalix BioTherapeutics Inc.2025 Big Picture & Reliable Intraday Trade Plans - Newser
Backtesting results for Protalix BioTherapeutics Inc. trading strategiesChart Signals & Verified Short-Term Plans - Newser
Is it time to cut losses on Protalix BioTherapeutics Inc.2025 Stock Rankings & Daily Market Momentum Tracking - Newser
Historical volatility pattern of Protalix BioTherapeutics Inc. visualizedJuly 2025 News Drivers & AI Based Buy/Sell Signal Reports - Newser
Live market analysis of Protalix BioTherapeutics Inc.Quarterly Profit Review & Low Drawdown Momentum Trade Ideas - Newser
Applying sector rotation models to Protalix BioTherapeutics Inc.2025 Volatility Report & Free Weekly Watchlist of Top Performers - Newser
Institutional scanner results for Protalix BioTherapeutics Inc.Quarterly Profit Report & Daily Growth Stock Tips - Newser
Protalix BioTherapeutics Inc. stock outlook for YEARJuly 2025 Snapshot & Fast Moving Stock Watchlists - Newser
Will Protalix BioTherapeutics Inc. price bounce be sustainableMarket Volume Summary & Weekly High Conviction Ideas - Newser
Biotech Innovator Protalix BioTherapeutics to Showcase ProCellEx Platform at Q3 Investor Summit Virtual - Stock Titan
Protalix BioTherapeutics Inc. stock trend outlook and recovery path2025 Price Targets & Reliable Breakout Stock Forecasts - Newser
Protalix BioTherapeutics to present at Investor Summit Virtual - Proactive financial news
How high can Protalix BioTherapeutics Inc. stock goStop Loss & Low Drawdown Investment Strategies - Newser
Pattern recognition hints at Protalix BioTherapeutics Inc. upsideIPO Watch & Accurate Entry and Exit Point Alerts - Newser
Finanzdaten der Protalix BioTherapeutics Inc.-Aktie (PLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.33%
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):